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Test-negative studies recruit cases who attend a healthcare facility and test positive 
for a particular disease; controls are patients undergoing the same tests for the same 
reasons at the same healthcare facility and who test negative. The design is often used 
for vaccine efficacy studies, but not exclusively, and has been posited as a separate 
type of study design, different from case–control studies because the controls are not 
sampled from a wider source population. However, the design is a special case of a 
broader class of case–control designs that identify cases and sample ‘other patient’ 
controls from the same health care facilities. Therefore, we consider that new insights 
into the test-negative design can be obtained by viewing them as case–control studies 
with ‘other patient’ controls; in this context, we explore differences and 
commonalities, to better define the advantages and disadvantages of the test-negative 
design in various circumstances. The design has the advantage of similar participation 
rates, information quality and completeness, referral/catchment areas, initial 
presentation, diagnostic suspicion tendencies, and preferences by doctors. Under 
certain assumptions, valid population odds ratios can be estimated with the test-
negative design, just as with case–control studies with ‘other patient’ controls. 
Interestingly, directed acyclic graphs are not completely helpful in explaining why the 
design works. The use of test-negative designs may not completely resolve all 
potential biases, but they are a valid study design option, and will in some 
circumstances lead to less bias, as well as often being the most practical option.  













Test-negative studies are frequently used in epidemiology, particularly in the context 
of vaccine effectiveness or antibiotic resistance,
1-8
 but also in studies of risk factors 
for various conditions such as venous thrombosis
9
 or Reye syndrome.
10
 Such studies 
involve recruiting cases who attend a healthcare facility and test positive for a 
particular disease; controls are then patients undergoing the same tests for the same 
reasons at the same healthcare facility and who test negative. Although this approach 
is widely used, there is some debate and confusion about what type of study this is, 
and what the potential advantages, disadvantages, and biases are. We will argue that 
the test-negative design can be seen as belonging to a wider class of case–control 
studies that use ‘other patient controls’ (i.e. other attendees of the same or similar 
healthcare facilities). This perspective clarifies the status of test-negative studies as a 
design option, clarifies discussions about potential biases, and offers additional 
insights into its strengths and weaknesses.  
History and terminology 
To the best of our knowledge, Miettinen was among the first to describe in full the 
basic idea of test-negative case–control studies in his 1985 “Theoretical 
Epidemiology” [See
11
 page 79]: He argued that “An idealized reference series, as a 
sample of that base would consist of a phenocopy of the illness under study, occurring 
independently of the determinant”. He explained that the persons or events making up 
this reference series would come under attention in the same way as the cases, but that 
a last-minute differential diagnosis would separate them from the cases. That 
reference series would share all the selectivity of the cases, and therefore would 









Thus, Miettinen essentially describes these as case–control studies, albeit with a non-
standard control group.  
In the literature about test-negative designs for vaccine effectiveness, the 1980 study 
on “Pneumococcal Disease after Pneumococcal Vaccination” by Broome et al.
12
 is 
often credited for being the first test-negative vaccine effectiveness study. As quoted 
from the abstract of that paper, the design aimed to compare the frequency of different 
serotypes in “...35 isolates of Streptococcus pneumonia isolated from blood or 
cerebrospinal fluid one month or longer after the patient had received commercially 
available pneumococcal vaccine with serotypes of 392 isolated from unvaccinated 
persons surveyed in a study of the nationwide distribution of pneumococcal 
serotypes.” Both series consisted of body material samples of persons with 
pneumococcal disease, and thus represented incident cases of disease. The analysis 
(See the equations in the Methods section of Broome et al.
12
) is a comparison between 
the incidence of “pneumococcal disease with serotypes present in the vaccine” 
between two cohorts of unknown size: one vaccinated and one not. However, the 
relative size of the unknown cohorts is approximated by the relative numbers of 
persons with pneumococcal disease with “serotypes not present in the vaccine”, 
emanating from these two cohorts. This approach is commonly known as a 
Proportional Mortality (or Morbidity) Ratio study in occupational epidemiology, 
(see
13
 page 72) and can be rewritten as a Morbidity Odds Ratio analysis (the latter is 
essentially a case–control study sampling from a 2x2 table comparing exposed and 
unexposed cohorts
14
). This proportional estimation was later referred to as an ‘indirect 












In recent reviews and publications about vaccine effectiveness of influenza 
vaccination, the ‘test-negative design’ is posited as a separate entity, possibly 
different from case–control studies.
1, 4, 16
  A focused discussion on a particular design 
in a particular application (such as vaccine effectiveness) has benefits, as it is rooted 
in and enriched by subject matter knowledge. On the other hand, we consider that the 
test-negative design has commonalities with a broader class of designs that identify 
cases and sample ‘other patient’ controls from the attendees of the same or similar 
health care facilities.  In this general class of case–control studies, controls are 
intended to be sampled from the catchment population for a healthcare facility; this is 
achieved by sampling controls from persons who present at the same or similar 
facilities but have a different disease. Common examples of this approach include 
hospital-based case–control studies (like the first case–control studies on smoking and 
lung-cancer
17-19
), or case–control studies in which cases and controls are chosen from 




There are various reasons for using other patient controls.
20, 21
 Sometimes this is the 
most practical option, if cases can only be identified through a particular healthcare 
facility, and the catchment area for the facility cannot be enumerated; other patient 
controls therefore represent a practical option. Other reasons include the need to 
address several difficult-to-define and difficult-to-control selection biases, such as 
diagnostic referral bias; i.e., if not all relevant cases can be identified, and there are 
selection processes which influence case identification, then other patient controls 
may be used if it is considered that they will have gone through the same selection 









cancer or congenital malformations where other cancers or other malformations are 
used as controls, sometimes in a sensitivity analysis.
22
  
Test-negative designs are a particular type of such case–control studies, the distinctive 
feature being that they sample controls from persons who present themselves with 
similar signs and symptoms (to those of the cases) to the same health care facilities, 
but in which the case-disease of interest is ruled out by the test. In this situation, the 
(test-negative) controls will have other reasons for their signs and symptoms (e.g., in 
vaccine effectiveness studies of influenza, controls may have been infected with other 
viruses that cause flu-like symptoms), but may be assumed to have gone through a 
similar selection and referral process to that of the (test-positive) cases. Test-negative 
sampling of controls has been applied to studies of widely diverse topics, such as oral 
contraceptives and venous thrombosis,
9
 Reye syndrome and aspirin use,
10
 and risk 
factors for antibiotic resistance.
2
 
In this paper, we will discuss test-negative designs in this broader framework of case–
control studies with other patient controls, to define more clearly their benefits and 
their drawbacks in several circumstances. We will argue that test-negative studies 
have their own characteristics and potential advantages, disadvantages and biases, but 
they also have much in common with other case–control studies which use other 
patient controls. The consideration of test-negative studies can therefore be enhanced, 
and the potential biases clarified, by considering the broader literature on such 
studies. We will focus on biases that may occur in test-negative studies in comparison 
with the gold standard of an ideal population-based case–control study with complete 
case-ascertainment, random sampling of controls (possibly conditional on certain 
characteristics), correct classification of exposure, and 100% response rates. Such a 













 page 112 ). Implicit in this design is that it 
involves a primary definition of the source population,
11
 i.e., a population that is 
defined beforehand and from which cases emanate and controls are selected over 
calendar time (in the past or in the future). In focusing on the potential differences 
with this design, we will not consider potential problems that the test-negative design 
may have in common with all case–control studies. Thus, our aim is to discuss how a 
test-negative study can yield the same findings as would have been obtained with the 
gold-standard approach; we acknowledge that even a gold-standard study may yield 
biased findings (e.g. due to residual confounding) in comparison with an idealized 
randomized controlled trial, but we will not consider these more general issues here.  
Also, we will refrain from discussing issues specific for test-negative designs for 
influenza vaccine effectiveness studies because these issues have been discussed 
extensively elsewhere
1, 4-8
, and because any exposure–disease association studied by 
test-negative designs will have its own particularities. Rather we focus on the general 
case–control aspects of test-negative designs.  
General principles of case–control studies with other patient controls 
We will briefly consider the general issues of case–control studies with ‘other patient’ 
controls before considering the specific issues of test negative studies.  We will do so 





Selection bias can occur in case–control studies due to biased selection of cases 
and/or controls from the source population, either by choices of the investigators, or 
in the pathways that make patients present themselves in particular health care 









If all of the cases generated by the source population over the risk period (i.e., from an 
idealized cohort) are included in a case–control study then there can be no selection 
bias with regards to selection of cases. However, selection bias can occur if only some 
cases are identified, and this is related to the exposure under study.  
Selection bias can also occur due to biased selection of controls. According to 
standard theory, controls should be sampled (conditionally) at random from the 
source population and risk period, and should be free of and at risk of the study 
disease at the time of sampling – thereby the controls should represent the exposure 
distribution of the source population for cases. However, if the cases are identified 
through a healthcare facility or group of facilities (e.g. a particular hospital, or groups 
of hospitals, or in a series of different outpatient clinics or GP practices), then the 
source population (the catchment or referral area of the facilities) may be difficult to 
enumerate and may have socio-economic, lifestyle and/or health characteristics that 
differ from the general population. Choosing controls from the general population 
may thus lead to bias with regard to the estimation of the prevalence of exposure(s) in 
the true source population. Therefore controls are often chosen from patients referred 
to the same facility for symptoms or diseases with similar referral patterns (i.e. 
patients who would have come to that hospital for the case-disease). This approach 
was used, for example, in several of the first case–control studies of lung cancer and 
smoking that included other patients in the same wards or other cancer patients.
17-19
 
This approach has continued to be used in cancer epidemiology, exploiting the 
existence of cancer registries.
20
  It has also been advised and commonly used in case–












 A problem also arises if a subgroup of cases with specific characteristics is targeted 
for investigation of those characteristics, for example, in studies of risk factors for 
urinary tract infections with bacterial strains that are resistant to particular antibiotics. 
If one were to sample controls from the general population, the case–control analysis 
might mix up general risk factors for urinary tract infections with specific risk factors 
for infection with a resistant strain. Therefore, such studies are often done by using 
controls who also have urinary tract infections, but with sensitive strains: cases and 
controls have the same disease by the same general agent (e.g., urinary tract infection 
by E. coli) but with different antibiotic sensitivity characteristics.
26
  As antibiotic 
sensitivity does not influence the virulence of the bacteria (their propensity to be 
infective and/or invasive), both groups will have similar risk factors for urinary tract 
infections. However, over and above these general risk factors, the cases will have 
additional risk factors for being differentially infected with resistant strains. 
A further potential problem with biased selection of controls involves self-selection 
mechanisms, leading to differences in participation rates. While persons who acquired 
a particular disease and become cases may quite readily participate in a study about 
past exposures, this may not be true for general population controls. In contrast, other 
patient controls may more readily participate, given that they might have similar 
concerns to the cases about the causes of their disease or their signs and symptoms.  
Information bias 
Even if all cases (or a random samples of cases) are identified from the source 
population and risk period, and controls are sampled in an unbiased manner, bias can 
still occur because of differences in the validity of exposure information in cases and 
controls. A particular concern is that persons with disease may have a much better 









exposures ‘out of the blue’. This is a common experience in studies of events during 
pregnancy and the occurrence of congenital malformations: mothers who deliver a 
child with a congenital malformation may recall and report many possible causes that 
occurred during the pregnancy, while mothers who delivered a seemingly healthy 
baby may have less recall of anything untoward during their pregnancy. That is the 
reason that investigators have used mothers with babies with a different congenital 




Confounding can occur in all epidemiologic studies, and is not specific to studies 
involving other patient controls. However, studies with other patient controls can be 
used in innovative ways to control for types of confounding that are difficult to 
specify or measure. An example arises from studies of specific asthma medications as 
a cause of asthma mortality. A series of case–control studies in New Zealand sampled 
asthma deaths as cases, while controls were patients who were admitted to hospital 
with a non-fatal, but apparently severe enough asthma attack to warrant 
hospitalisation. The reason for using ‘hospital controls’ was to achieve ‘indirect 
matching’ on asthma severity, since there was prior evidence that asthmatics who died 
and asthmatics who were admitted to hospital with a non-fatal attack were similar 
with regards to chronic asthma severity, which is a major determinant of 
prescribing.
27
 On the contrary, it was known that asthmatics who were never admitted 
to hospital generally had a lower chronic severity. The contrast was therefore between 
asthmatics who had a severe attack and died (often without making it to hospital), and 
asthmatic who had a severe attack and survived long enough to make it to hospital 










The meaning of the odds ratio with ‘other patient controls’ 
As the theory of ‘modern’ case–control studies has evolved, it has become generally 
accepted that the controls should reflect the exposure prevalence (past or recent or 
cumulative, etc) of the source population that generated the cases over the relevant 
risk period.
28
 This permits a straightforward interpretation of  case–control odds ratios 




Patients with other diseases are mentioned as potential sources of controls in several 




 page 119). Patients with 
other diseases can be seen as sampled from a ‘secondary base’, i.e., a source 
population that is defined only after cases are sampled, and by the way the cases are 
sampled, e.g., the catchment population of a medical facility or a registry (See
11
 page 
54-55). Patients with other conditions will reflect that source population. The term 
‘secondary’ distinguishes from the ‘primary’ base, mentioned above when describing 
the ‘gold standard’. 
A caveat that was repeatedly emphasized in the literature
11, 20, 21, 25
 was that the 
control condition(s) should not be associated positively or negatively with the 
exposure under study. This is obvious nowadays:  one would not, for example, 
consider using patients with other lung conditions as controls in a study of smoking 
and lung cancer as many such conditions are also associated with smoking. In the 
early days it was not that obvious. For example, Wynder et al.
17
 in their epochal 1950 
study on smoking and lung cancer used controls from a chest disease ward for a 
sensitivity analysis about possible interviewer bias (interviewers were not aware of 
the diagnosis and all patients had chest disease); they were perhaps lucky to find a 









important consideration in pharmacoepidemiologic case–control studies wherein it 
was proposed that control diseases should neither be positively nor negatively 
associated with the drug exposure under investigation.
25
 And if there is an association, 
the important consideration then becomes whether the design would underestimate or 
overestimate exposure in the controls with respect to that in the source population. 
Specific characteristics of test-negative studies: opportunities and drawbacks 
In test-negative studies, controls are enrolled from those who present with similar 
signs and symptoms, preferably sampled from a time frame before the final diagnosis; 
and usually from the same health care facilities. Given that the controls have similar 
signs and symptoms but not the disease of interest, there will be other reasons for 
their signs and symptoms, such as other diseases. In a broader sense, the ‘test’ in the 
‘test-negative design’ is a procedure to achieve a diagnosis, and the controls can also 
be viewed as ‘negative to the diagnosis’ of the case disease of interest; thus the design 
might also be described as the ‘same symptom – different diagnosis’ design.  
We will consider several examples of test-negative studies in the light of the general 
principles of using other patient controls. We will consider the potential biases that 
test-negative study designs try to remedy, as well as potential biases that they may 
create. In each instance, some potential biases relate to the selection and/or 
classification of the cases, or the controls, or to both. 
The potential selection biases that test-negative studies intend to address include 
diagnostic suspicion and/or referral mechanisms that affect case-ascertainment. In the 
study of oral contraceptives as a cause of venous thrombosis, the argument was used 
that persons with milder signs and symptoms would only be diagnosed or referred for 
diagnostic evaluation if they used oral contraceptives, thus biasing the estimate of 









solution was to stratify for severity of illness, on the assumption that case-
ascertainment would be almost complete in the group with very severe signs and 
symptoms, and that oral contraceptive use therefore would not affect referral in this 
subgroup. From such stratification/restriction it was found that the odds ratio was 
even higher in persons with severe symptoms (which was the inverse of what would 
be expected if the hypothesized selection bias existed).
30
 A more recent solution was 
to sample cases and controls from the diagnostic facility to which they were referred 
in order to rule out venous thrombosis by imaging.
9, 31
 The cases were persons in 
which the suspicion was confirmed by imaging; the controls were those in which the 
imaging did not confirm the suspicion (in those patients there would be other reasons 
for their signs and symptoms). Thus, all cases and controls would be referred with 
similar reasons to suspect venous thrombosis (i.e., similar signs and symptoms). In 
these more recent studies that used a ‘test-negative’ design, the elevated odds ratio of 
venous thrombosis with oral contraceptives was confirmed.  The earliest approach to 
remedy this potential selection bias involved ‘general population’ controls, with the 
cases being stratified or restricted on severity; the later approach involved using 
‘other patient’ controls. Both approaches yielded similar results, which were of the 
same magnitude as that of the original studies in which the bias might allegedly have 
occurred – and in which no precaution against this bias was taken. 
A second and related mechanism of biased case-ascertainment relates to ‘health-
seeking behavior’.  This possibility was raised in studies of influenza vaccine 
effectiveness.  It is possible that persons who present themselves with milder forms of 
flu-like symptoms may be persons who are more prone to seeking health care, and 
that these persons would also be more prone to have been vaccinated for influenza 









with potential influenza to a health care facility were virologically tested as to 
whether they were infected with an influenza virus or not. The former become (test-
positive) cases, the latter become (test-negative) controls.
1
 This makes it clear that the 
distribution of health seeking behavior amongst these cases and controls should be 
similar: some would present with very severe symptoms (and the problem of health 
seeking behavior is moot), while others would present with mild symptoms; in the 





 also consider the gradient of health seeking behavior, which in their 
opinion opens the possibility that the test-negative design would not completely block 
the effect of health seeking behavior. However, this would only apply if the average 
level (and range) of health seeking behavior was different in those who are test 
positive and those who are test negative. This is not different from the situation when 
health seeking behavior is a dichotomous variable.  Indeed, one can imagine some 
‘hypochondriac’ persons who will rush to a doctor with very mild symptoms, while 
others, somewhat more robust, will visit the doctor only when they have severe 
symptoms. Amongst the ‘robust’, some persons with mild influenza symptoms will 
not be identified because they did not present themselves, but the same would happen 
if they had a mild non-influenza viral infection and therefore would be potential 
controls. Thus, in a test-negative design the controls will certainly meet a kind of 
counterfactual definition of ‘controls [that] would have been identified as cases had 
they developed the health outcome of interest during the period of observation of the 
study base.’
32
 Self-selection in presenting oneself to a health care facility is in fact a 
general issue in case–control studies wherein a visit to a health care facility is needed 










This reasoning also makes it clear that it does not help to have better diagnostic 
criteria for the case-condition to circumvent this selectivity in self-presentation. Of 
course, good case-definitions, can be important for other purposes, such as reducing 
misclassification. Stratification according to severity of symptoms is an analytic 
strategy described above for standard case control studies, such as the studies of oral 
contraceptives and venous thrombosis, as a safeguard against diagnostic suspicion 
bias.
30
 As explained above, test-negative design on the same association made the 
potential bias equally strong amongst cases and controls.
9, 31
  
Selection bias and confounding were of particular concern in the study of aspirin as a 
potential cause of Reye syndrome in children.
10
 A noteworthy aspect of this example 
is that exposure to a medication can be a consequence of early symptoms. In this 
situation, choosing controls from other attendees at the same healthcare facility with 
similar signs and symptoms can have methodologic advantages. Reye syndrome is a 
rare but potentially lethal complication of some viral infections in children (in 
particular chickenpox) characterized by failure of several organs (liver, brain). Based 
on case series and initial case–control studies, it was postulated that the risk of the 
syndrome was highly increased if children with such viral diseases received aspirin to 
alleviate the signs and symptoms of that viral disease. This hypothesis was met with 
strong skepticism because it was held that giving aspirin to children with symptoms of 
viral origin would be a standard medical therapy, i.e. that there would be confounding 
by indication. Because of that concern, a case–control comparison was set up with 
controls being chosen from children with alternate conditions, i.e., children who also 
had been seen with similar initial symptoms in the same health care facilities. In those 
children the diagnosis of Reye syndrome might have been considered, but their 









confirmed the association of aspirin and Reye syndrome. A nice analytic feature was 
the restriction to children who had either received aspirin or paracetamol for their 
viral symptoms; the odds ratio was 36 (95% CI 4.2 – 288), which was of a similar 
order of magnitude as found in other studies, among which one with several different 
control groups.
33
 The study tried thus to mimic a randomized experiment in children 
with viral diseases: either give paracetamol or aspirin.  
Another example of potential confounding by health seeking behavior, as well as 
confounding by indication, occurred in a study that assessed protein pump inhibitors 
as risk factors for acquiring a urinary infection with an E. coli strain with multiple 
resistance to antibiotics, instead of with a strain that is generally sensitive to 
antibiotics.
26
 A potential problem is that antibiotic cultures are not carried out in many 
patients with signs and symptoms of urinary tract infection: when it is a first or an 
occasional urinary tract infection (in particular in women), often standard antibiotic 
treatment is given without cultures. On the other hand, patients with persistent or 
recurrent urinary tract infection and/or pre-existing medical diseases are more likely 
to have urine cultures taken and tested for antibiotic resistance; the same patients may 
also use protein pump inhibitors much more often. Because all associations are 
positive, including only patients with urine cultures in the study may have induced a 
selection bias that diminishes the association with protein pump inhibitors, which can 




It is interesting to note that in the examples, several potential selection mechanisms 
are addressed at once by the test-negative design. The design has the advantage of 









referral/catchment areas, similar initial presentation, similar diagnostic suspicion 
tendencies, and finally similar preferences or choices by doctors. 
Westreich et al., in a commentary entitled: “Beware of the test-negative design”,
16
 
echo the view that test-negative designs are not really  case–control studies as controls 
are not sampled at random from the source population. However, as noted above, 
there is a broad class of case–control studies in which controls are sampled from other 
health care attendees within the source population, and the test-negative design falls 
within this class. Also, it has been argued that the test-negative design is a cohort with 
some incomplete follow-up.
1, 34
  However, there is no follow-up happening in a test-
negative design: case or control status is determined at a single point in time: the time 
of the test.  
As mentioned, the study of vaccine effectiveness that is considered the first used the 
reasoning of a Proportional Morbidity Ratio analysis (which one might recast as a 
case–control analysis) sampled from two cohorts.
12
 As described above, under certain 
assumptions, valid population odds ratios can be estimated with controls that are not 
sampled from the source population, e.g. with other patient controls. The views 





page 119) and with several reviews that have upheld the validity of the test-negative 
design,
4, 5, 35
 amongst others by simulation studies and probability modelling. 
According to Jackson et al.,
5
  “With the assumptions that (a) the distribution of non-
influenza causes of acute respiratory infections does not vary by influenza vaccination 
status, and (b) vaccine effectiveness does not vary by health care-seeking behavior, 
the vaccine effectiveness estimate from the sample can generalized to the full source 
population that gave rise to the study sample.” This statement is logical if one sees it 
in the light of a case–control design with ‘patient controls’. Shi et al.
7









qualification that “the confounding effects resulting from non-random vaccination are 
similar for influenza and non-influenza acute respiratory infections” – we agree with 
this additional criterion with the proviso that it is the residual confounding effects 
(after adjustment for known confounders) that are relevant here. 
The general caveat that the control condition should not be associated with the 
exposure, either positively or negatively is not often invoked in discussions of test-
negative designs, in contrast with the more general literature on case–control studies 
with other patients as controls. In pharmacoepidemiology there is often careful 
consideration of which patients can or cannot be included as ‘other patient controls’. 
In contrast, in test-negative designs there is usually little effort to know what other 
diseases might have caused the same signs and symptoms in the controls that tested 
negative for the case disease. This seems to be an under-evaluated aspect of test-
negative designs for vaccine effectiveness. As an example of the subtleties involved, 
in  the instance of studies of venous thrombosis and the risk of travel a test-negative 
design found no association with long-haul flights, in contrast to a host of other well-
done case–control and cohort studies. 
36
 The reason might be that long-haul flights 
may also cause leg symptoms such as edema, without an underlying venous 
thrombosis; however, leg edema is also possible warning sign of venous thrombosis. 
Thus a referral for a patient with leg edema might be influenced by the history of a 
recent long flight and will yield controls with a similar flying history as the cases. We 
learn from this example that it may be a particular challenge to identify a phenocopy 
with the same symptoms, but which is independent of the determinant; however, this 











In outlining the arguments in this paper, we have not made use of directed acyclic 
graphs (DAGs), for reasons fully explained in the eAppendix; 
http://links.lww.com/EDE/B579, as we felt that the test-negative design involves 
potential biases that are not readily represented in DAGs, and that the previously 
published DAGs each had their merits but were wanting in other respects, in 
particular because the DAGs do not explain why the design works. Indeed, the test-
negative design may reduce certain selection and confounding biases, but the biases 
may not completely disappear; the common problem with DAGs is that they do not 
address the quantitative strength of the associations that are potential biases and that 
are diminished in a test-negative design.  
In this paper, we have described the test-negative design as belonging to a family of 
similar designs where cases and controls are selected from patients from the same or 
similar health care facilities. It represents a subtype of this approach, where controls 
are patients with similar clinical signs and symptoms who have tested negative for the 
‘case disease’ in a further lab-based or imaging procedure.  
These studies can give valid causal estimates of odds ratios in the source population, 
albeit only under certain assumptions. The use of such designs may not completely 
resolve all potential biases, but will in some circumstances lead to less bias, as well as 
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